UNASSIGNED: @entity4294 ( @entity4294 ) is usually performed in @entity1 undergoing pancreatic surgery for chronic @entity788 . In the present series, @entity4294 was offered also to @entity1 undergoing pancreatic surgery for both non-malignant and malignant diseases, either having completion pancreatectomy as treatment for severe pancreatic fistulae (n=21) or extensive distal pancreatectomy for @entity5 of the pancreatic neck (n=19) or pancreatoduodenectomy because of the high risk of @entity3472 (n=32). Fifty-eight of 72 @entity1 who were eligible to this broader spectrum of indication actually received @entity4294 . There was no evidence of a higher than expected rate of major complications for pancreatectomy. Forty-five @entity1 receiving @entity4294 were still alive at the time of the last scheduled follow-up (1,375  365 days). Eighteen out of 19 (95%) and 11 out of 39 (28%) @entity1 reached insulin independence after partial or total pancreatectomy, respectively. The metabolic results were dependent on the transplanted islet mass. Thirty-one out of 58 @entity1 had @entity5 or periampullary region and only 3 @entity1 developed ex-novo liver metastases after @entity4294 (median follow-up 914  382 days). Our data demonstrate the feasibility, efficacy, and safety of @entity4294 for a broader spectrum of clinical indications beyond chronic @entity788 . This article is protected by copyright. All rights reserved.

Autologous islet transplantation in XXXX requiring pancreatectomy: a broader spectrum of indications beyond chronic @entity788 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity4294 :: ('MESH:D007516', 'Disease') :: ['Islet autotransplantation', 'IAT'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'malignant diseases of the pancreas'] @entity3472 :: ('MESH:D010185', 'Disease') :: ['pancreatic fistula']
@entity1 :: (9606,Species) :: ['patients']
